(CercleFinance.com) – Valneva retreats on the Paris Stock Exchange on Wednesday morning after revealing annual revenue forecasts below market expectations.
The vaccine specialist has raised its sales forecasts for 2024, now expecting total turnover between 170 and 190 million euros, compared to 153.7 million euros in 2023.
Invest Securities analysts nevertheless point out that this forecast, even improved, still remains below the consensus, which targets around 215 million euros this year.
For the 2023 financial year, its net loss narrowed to 101.4 million euros, compared to 143.3 million in 2022.
With cash of 126.1 million euros at the end of 2023, up 95 million euros year-on-year, Valneva said it was entering the 2024 financial year ‘in a good financial position’.
However, the stock fell by 4.5% around 10:20 a.m., appearing among the bottom performers in the SBF 120 index alongside Kering (-14%).
Copyright © 2024 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
